Blood Pressure Management and Arrhythmia Risk with Mirabegron

Hypertension as a Modifiable Risk Factor

Uncontrolled hypertension markedly increases the incidence of atrial fibrillation and ventricular arrhythmias, especially in patients with left‑ventricular hypertrophy. (European Society of Cardiology, 2017) 1
In patients with atrial fibrillation, systolic blood pressure ≥ 140 mm Hg raises the risk of ischemic stroke (hazard ratio ≈ 1.5), hemorrhagic stroke (HR ≈ 1.85), and major bleeding (HR ≈ 1.14) among those receiving anticoagulation. (European Society of Cardiology, 2017) 1

Mirabegron is contraindicated in individuals with severe uncontrolled hypertension (SBP ≥ 170–180 mm Hg or DBP ≥ 100 mm Hg); blood‑pressure control should first be achieved with ACE inhibitors, ARBs, or β‑blockers as appropriate for the underlying arrhythmia. (European Society of Cardiology, 2017) 2
When hypertension is well‑controlled, mirabegron may be initiated with routine blood‑pressure monitoring; no specific arrhythmogenic safety signal has been identified. (European Society of Cardiology, 2017) 1

The primary therapeutic goal before adding mirabegron is to achieve a target systolic blood pressure < 140 mm Hg to mitigate stroke and bleeding risks in anticoagulated patients. (European Society of Cardiology, 2017) 1
Rate control should be established with β‑blockers or nondihydropyridine calcium‑channel blockers prior to mirabegron therapy. (American Heart Association, 2014; American College of Cardiology, 2014) [3][4]

Management should prioritize avoidance of hypokalemia and the use of QT‑prolonging medications. (European Society of Cardiology, 2017) 2
Optimal blood‑pressure control and regression of left‑ventricular hypertrophy with appropriate antihypertensive agents are essential to reduce ventricular arrhythmia risk. (European Society of Cardiology, 2017) 1

No dedicated safety data exist for mirabegron in patients with severe heart failure (NYHA class III–IV). (American Heart Association, 2014; American College of Cardiology, 2014) [3][4]
In compensated heart‑failure patients with preserved ejection fraction, the initial strategy should focus on rate control using β‑blockers or nondihydropyridine calcium‑channel blockers before considering mirabegron. (American Heart Association, 2014; American College of Cardiology, 2014) [3][4]
If heart failure is decompensated, alternative over‑active‑bladder therapies should be preferred over mirabegron. (American Heart Association, 2014; American College of Cardiology, 2014) [3][4]

The European Association of Urology guidelines and FDA labeling data indicate that mirabegron is associated with several adverse effects, including hypertension (7.5-11.3% vs 7.6% placebo), nasopharyngitis (3.5-3.9% vs 2.5% placebo), urinary tract infections (2.9-4.2% vs 1.8% placebo), headache (2.1-3.2% vs 3.0% placebo), and constipation (1.6% vs 1.4% placebo) 5

The European Association of Urology recommends monitoring for hypertension, as it is the most significant concern and occurs predominantly in patients with baseline hypertension, with an incidence of 7.5-11.3% vs 7.6% placebo 5
Nasopharyngitis occurs in 3.5-3.9% of patients vs 2.5% placebo, according to the European Association of Urology guidelines and FDA labeling data 5
Urinary tract infections occur in 2.9-4.2% of patients vs 1.8% placebo, as reported by the European Association of Urology guidelines and FDA labeling data 5
Headache occurs in 2.1-3.2% of patients vs 3.0% placebo, according to the European Association of Urology guidelines and FDA labeling data 5

The European Association of Urology guidelines state that mirabegron is contraindicated in patients with severe uncontrolled hypertension, with a strength of evidence level of high 5, 6, 7

The European Association of Urology guidelines indicate that mirabegron is well tolerated in elderly patients (≥65 years) and those with multiple comorbidities, with a low risk of adverse effects 5, 6, 8, 9

The European Association of Urology guidelines state that mirabegron has an absolute contraindication in patients with severe uncontrolled hypertension, with a strength of evidence level of high 5, 6, 7

The European Association of Urology guidelines report that long-term data on efficacy and safety of mirabegron in men of any age with lower urinary tract symptoms are not available, with a strength of evidence level of low 5, 6
Studies up to 12 months demonstrate maintained efficacy with acceptable tolerability, according to the European Association of Urology guidelines, with a strength of evidence level of moderate 5